Sonoma Biotherapeutics | Biotech/Pharma | Standout | Standout

Sonoma Biotherapeutics

112 employees

Biotech/Pharma

Series B · $335.0M

Open positions (1)

Director, Regulatory Affairs

South San Francisco, California

Company details

Team Size112

IndustryBiotech/Pharma

Funding

Total raised

$335.0M

Last stage

Series B

Investors

ARCH Venture Partners

Lilly Asia Ventures

Ally Bridge Group

StandoutYBacked by Y Combinator · P26

“LeBron has an agent. Why don’t you?”

— Now you have one too.

Earn $3,000

ProductHow it works For talent For companies Browse jobs Browse companies

CompanyAbout Blog Careers

ConnectTwitter / X LinkedIn

Standout.

Privacy Terms

Alexandria Venture Investments

8VC

Founders

Alexander Rudensky

Co-founder of Sonoma Biotherapeutics and leading researcher in regulatory T cell biology.

Fred Ramsdell

Veteran biotechnology leader in immunology with nearly three decades of experience. Led the team that discovered and characterized FoxP3, a gene critical to regulatory T cell function. Previously CSO at the Parker Institute for Cancer Immunotherapy.

Jeffrey Bluestone

One of the leading immunologists in T-cell activation and immune tolerance research. Co-founded Sonoma Biotherapeutics and served as its President and CEO before transitioning to Advisor and Board Member in November 2025. Previously President and CEO of the Parker Institute for Cancer Immunotherapy.

What happens next.

No applications, no recruiter spam. Just the intro.

Confirm the fit

A few questions to make sure this role is the right shape for you. Two minutes.

I pitch you to the company

I write the intro, send it to the founder, and handle the back-and-forth.

A meeting lands on your calendar

If they’re a yes, I book the chat. You show up — that’s the whole job-hunt.